Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/263068
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Different neurocognitive profiles of risperidone and aripiprazole in the FIRST episode of psychosis: A 3-year follow-up comparison |
Autor: | Setién-Suero, Esther; Ortiz-Garcia de la Foz, Victor; Suárez-Pinilla, Paula; Crespo-Facorro, Benedicto CSIC ORCID CVN; Ayesa Arriola, Rosa | Palabras clave: | First episode of psychosis Cognition Risperidone Aripiprazole |
Fecha de publicación: | 30-ago-2021 | Editor: | Elsevier | Citación: | Progress in Neuro Psychopharmacology and Biological Psychiatry 110: 110309 (2021) | Resumen: | Cognitive deficits have been recognized as a central feature of schizophrenia spectrum disorders. These deficits are often related to more severe negative symptoms, as well as a poorer adjustment in social functioning. Therefore, it is important to improve cognitive performance from the onset of the disease. In this study, we compared the effects of two atypical antipsychotics, risperidone and aripiprazole, on cognition. The data used in the present investigation were obtained from a large epidemiological cohort of patients with a first episode of psychosis who were treated in a longitudinal intervention programme. The patients included in the program were randomized to treatment with risperidone or aripiprazole and were assessed for cognitive function at baseline and 3 years later. The final sample consisted of 115 patients, 55 of whom were initially assigned to risperidone and 60 to aripiprazole. The groups did not show significant differences in their sociodemographic or clinical characteristics at intake. Longitudinal analyses showed that risperidone-treated patients improved in the processing speed domain at the 3-year follow-up, while the aripiprazole group showed better scores for the executive function domain. Our study shows slight differences between the effects of risperidone and aripiprazole on cognition, suggesting different patterns of efficacy on cognitive function that may warrant more thorough research to determine the beneficial effects of these drugs on cognition. Future studies should evaluate the effects of these treatments over longer follow-up periods using standardized tools for the assessment of cognitive function. | Versión del editor: | http://dx.doi.org/10.1016/j.pnpbp.2021.110309 | URI: | http://hdl.handle.net/10261/263068 | DOI: | 10.1016/j.pnpbp.2021.110309 | Identificadores: | doi: 10.1016/j.pnpbp.2021.110309 issn: 0278-5846 |
Aparece en las colecciones: | (IBIS) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
accesoRestringido.pdf | 15,38 kB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
1
checked on 24-may-2024
WEB OF SCIENCETM
Citations
1
checked on 25-feb-2024
Page view(s)
35
checked on 28-may-2024
Download(s)
4
checked on 28-may-2024
Google ScholarTM
Check
Altmetric
Altmetric
NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.